2.
Combination therapies of NK cells and therapeutic antibodies
| Antibody | Targeting antigen | Strategy | Condition | Stage of clinical development | NCT No. |
| NK cells, natural killer cells; NCT, national clinical trial; CD, cluster of differentiation; ADCC, antibody-dependent cellular cytotoxicity; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic lymphoma; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; SCCHN, squamous cell carcinoma of head and neck; GD2, ganglioside G (D2); SLAMF7, signaling lymphocytic activation molecule (SLAM) family member 7; MM, multiple myeloma; KIR, killer cell immunoglobulin-like receptor; NKG2A, natural killer cell group 2A receptor; MICA/B, MHC class I polypeptide-related sequence A/B. | |||||
| Rituximab | CD20 | ADCC | B cell NHL; CLL | FDA approved | |
| Ofatumumab | CD20 | ADCC | CLL | FDA approved | |
| Trastuzumab | HER2 | ADCC | HER2+ breast cancer; HER2+ gastric-esophageal junction carcinoma | FDA approved | |
| Cetuximab | EGFR | ADCC | Advanced SCCHN | FDA approved | |
| Dinutuximab | GD2 | ADCC | Pediatric neuroblastoma | FDA approved | |
| Elotuzumab | SLAMF7 | ADCC | MM | FDA approved | |
| Obinutuzumab | CD20 | Optimized ADCC | CLL | FDA approved | |
| Lirilumab | KIR2DL-1,
KIR2DL-2, KIR2DL-3 |
Combined with nivolumab and azacitidine; | Leukemia | Phase II | NCT02599649 |
| Combined with nivolumab and ipilimumab; | Cancer | Phase I/II | NCT01714739 | ||
| Combined with rituximab; | Lymphocytic leukemia | Phase II | NCT02481297 | ||
| Combined with elotuzumab and urelumab; | MM | Phase I | NCT02252263 | ||
| Combined with lenalidomide; | MM | Phase I | NCT01217203 | ||
| Combined with 5-azacytidine | Leukemia | Phase II | NCT02399917 | ||
| IPH4102 | KIR3DL2 | Immune checkpoint blockade | Cutaneous T-cell lymphoma | Phase I | NCT02593045 |
| Monalizumab | NKG2A | Monotherapy | Hematologic malignancies | Phase I | NCT02921685 |
| Combined with cetuximab; | Head and neck neoplasms | Phase I/II | NCT02643550 | ||
| Combined with afatinib and palbociclib; | Carcinoma, squamous cell of head and neck | Phase II | NCT03088059 | ||
| Monotherapy | CLL | Phase I/II | NCT02557516 | ||
| IPH4301 | MICA/B | Immune checkpoint blockade and ADCC | Preclinical | ||
| IPH52 | CD39 | Immune checkpoint blockade | Preclinical | ||
| IPH53 | CD73 | Immune checkpoint blockade | Preclinical | ||
| MEDI9447 | CD73 | Immune checkpoint blockade combination | Advanced solid tumor | Phase I | NCT02503774 |